ArticleJournal of contemporary brachytherapy2026
Collaborative design and additive manufacturing of a patient-specific high-dose-rate surface mold applicator for upper lip plesiotherapy.
Article in Journal of contemporary brachytherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To demonstrate the use of additive manufacturing in the design and fabrication of a high-dose-rate (HDR) plesiotherapy applicator for upper lip squamous cell carcinoma, with emphasis on design parameters, adequate dose coverage, and practical considerations for applicator customization. Material and methods: A 52-year-old male with persistent superficial upper lip squamous cell carcinoma, who previously underwent definitive chemoradiotherapy, was selected for HDR plesiotherapy boost to residual disease in an under-dosed region. Clinical measurements were performed by computer-aided design (CAD) for patient-specific surface mold incorporating pre-defined catheter geometry and mechanical features, to ensure applicator stability despite severe trismus. The applicator was fabricated using fused deposition modeling in flexible thermoplastic polyurethane (TPU). Dimensional verification, catheter patency testing, and clinical fitting were followed by conventional CT-based treatment planning. Results: The applicator was designed and fabricated within 72 hours, and radiotherapy planning followed GEC-ESTRO recommendations. Treatment planning achieved adequate target coverage, with high-risk clinical target volume (HR-CTV) D Conclusions: This report demonstrates the integration of additive manufacturing into a clinical brachytherapy workflow for a patient with upper lip squamous cell carcinoma, allowing fabrication of a patient-specific surface mold applicator with technical advantages in geometric accuracy and conformity to site-specific anatomic and functional constraints. Broader clinical implementation will require structured workflow integration, institutional planning of additive manufacturing logistics with in-house versus external production, standardization of quality assurance processes, and validation in larger clinical cohort studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.